Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024
Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
According to Mr Accuracy reports new survey, global Familial Amyloid Polyneuropathy Therapeutic market is projected to reach US$ 2067.8 million in 2029, increasing from US$ 1387 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029.
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market
Market OverviewThe market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying TherapiesThe development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR StabilizersTTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) TherapiesRNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver TransplantationIn some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic ConsiderationsThe global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and DevelopmentThe FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Familial Amyloid Polyneuropathy Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Prothena Corporation
Eidos Therapeutics
FoldRx Pharmaceuticals
Akcea Therapeutics
GlaxoSmithKline (GSK)
Greenovation Biotech GmbH
Segment by Type
Inotersen
Tafamidis
Patisiran
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Familial Amyloid Polyneuropathy Therapeutic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Familial Amyloid Polyneuropathy Therapeutic market is projected to reach US$ 2067.8 million in 2029, increasing from US$ 1387 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029.
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market
Market OverviewThe market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying TherapiesThe development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR StabilizersTTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) TherapiesRNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver TransplantationIn some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic ConsiderationsThe global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and DevelopmentThe FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Familial Amyloid Polyneuropathy Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Prothena Corporation
Eidos Therapeutics
FoldRx Pharmaceuticals
Akcea Therapeutics
GlaxoSmithKline (GSK)
Greenovation Biotech GmbH
Segment by Type
Inotersen
Tafamidis
Patisiran
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Familial Amyloid Polyneuropathy Therapeutic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source